J. SUBSEQUENT EVENTS	6 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]
J. SUBSEQUENT EVENTS	On April 3, 2018, the exercise price of the Company’s outstanding Series S warrants, which are publicly traded under the symbol “CVM WS” on the NYSE American, was changed to $1.75 per share for a two month period which will end on June 11, 2018. The exercise price had previously been changed to $3.00 for a three month temporary period ending on April 12, 2018. After June 11, 2018, the exercise price will revert back to $31.25 per share of common stock. Twenty-five (25) Series S warrants are required to purchase one share of common stock. The Series S warrants expire on October 11, 2018. Closing arguments in the arbitration against the former clinical research organization (CRO) for our Phase 3 trial concluded on April 25, 2018. The parties are now awaiting a decision from the arbitrator.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration